Reviews, GPCRs, and more G protein-coupled receptor-targeting antibody-drug conjugates: Current status Scientist/Tissue Culture Manager Postdoctoral Researcher Director - Targeted Oncology Senior Scientist - Antibody

The reported ACKR1 expression by macrophages in Hur et al. relied on using commercial anti-ACKR1 antibody

The conformation-selective antibody, Fab30, promotes partially activated βarr into the activated-like

structural studies of class IB phosphoinositide 3-kinases There is considerable interest in developing antibodies

Proteins were investigated<br />by western blotting using protein-specific antibodies against phospho-Smad2

GPCR Binders, Drugs, and more Engineered Human Antibody with Improved Endothelin Receptor Type A Binding A robust antibody discovery platform for difficult-to-express G protein-coupled receptors.

Twist Bioscience and Astellas Enter into Multitarget Antibody Discovery Research Collaboration Neurocrine

Great success has been reached with therapies based on the GLP-1 receptor monoagonism; therefore, a logical

Crinetics Pharmaceuticals Senior Director, In vitro pharmacology - Crinetics Pharmaceuticals In vivo Antibody

Inflammatory Bowel Disease (IBD) Domain Therapeutics and Chime Biologics Form Manufacturing Pact for Antibody

Domain Therapeutics Strengthens Its Intellectual Property for Its Series of Treg Depleting anti-CCR8 Antibodies

Training School on “Cell-based assays to study Adhesion GPCR function" (June 28 - 30, 2023) FREE Seminar Antibodies

Tokyo, Japan, organized by LINK-J Jounce takes the cash under amended deal with Gilead on anti-CCR8 antibody

Crinetics Pharmaceuticals Senior Director, In vitro pharmacology - Crinetics Pharmaceuticals In vivo Antibody

Confo Therapeutics Enters Into Research Collaboration For GPCR-Targeting Antibody Discovery With AbCellera

Acquire Inversago Pharma GPCR Events, Meetings, and Webinars NEW Antiverse: Reimagining Therapeutic Antibodies

from October 7th to 13th, 2024 Industry News Antiverse Raises £3.5M ($4.6M) to Advance Generative AI Antibody

Europe 2024 Conference and Exhibition June 2 - 4, 2024 | Chemotactic Cytokines GPCR Jobs NEW In vivo Antibody

specific expression of PRL3 in pediatric solid tumors for first-in-child use of PRL3-zumab humanized antibody

Domain Therapeutics and Chime Biologics announce manufacturing agreement  to advance novel anti-CCR8 antibody

clinical validation, as well as radiopharmaceuticals, including potential PET ligands, and suitable antibodies

Scientist/Tissue Culture Manager Postdoctoral Researcher Director - Targeted Oncology Senior Scientist - Antibody

Chimeric antigens displaying GPR65 extracellular loops on a soluble scaffold enabled the discovery of antibodies

Scientist/Postdoctoral Associate in Computational Chemistry/Biophysics Post-Doctoral Associate Team Leader Antibody

Announces Publication in Nature Communications Demonstrating First-Ever Structure of a Complex Between an Antibody-based

Hospital-University Research in Health (RHU) SPRINT consortium grant to progress its proprietary CCR8 antibody

autoimmunity in postural orthostatic tachycardia syndrome The binding mechanism of an anti-multiple myeloma antibody

into GPCR Function A homotrimeric GPCR architecture of the human cytomegalovirus revealed by cryo-EM Antibodies